The investments that the pharmaceutical company Takeda will make in Italy over the next five years amount to 275 million euros. And there will be a 100% increase in production, with 150 new hires at its two sites in Pisa and Rieti. This is what emerges from the 2021-2025 investment plan of the same company that was presented today in Rome. Active for over 240 years in more than 80 countries (with approximately 47,000 employees worldwide and over 1,100 in Italy), the biopharmaceutical company has decided to consolidate the production of plasma-derived drugs, of which it holds a significant market share worldwide.
In fact, over 550 employees work in Rieti engaged in plasma fractionation, from which fundamental proteins are obtained for the treatment of serious as well as rare diseases. While Pisa, through the work of the 200 employees employed, has become the main supplier of albumin for Takeda in developing countries. Speaking with a video message, the Minister of Foreign Affairs and International Cooperation, Luigi Di Maio, underlined “the presence of this Japanese company” which “has greatly contributed to increasing both employment as well as the professionalism and competence of the force. work employed in a sector, the pharmaceutical one, which is one of the flagships of the Italian system. Takeda’s success in Italy – he added – represents a strategic asset of the economic partnership between Italy and Japan, countries linked by a very long friendship and solid economic relations, strengthened also thanks to the dialogue built in the context of Italy-Japan Business Group “.
For the Minister of Economic Development, Giancarlo Giorgetti, “relations with Japan have always been marked by great collaboration. Takeda in Italy has two avant-garde realities: the fact that it has decided to invest again and in such an important way fills us with great satisfaction. The Government is at the side of those who intend to invest in Italy ».
“Both Italy and Japan are countries that stand out for the high quality and technology of manufacturing, and they share the demographic problem. For this reason, healthcare is certainly a sector in which our two countries will be able to continue to work together, achieving excellent results ”, underlined the ambassador of Japan to Italy, Hiroshi Oe.